ARWR Earnings

ARWR reported its FY2026Q1 earnings on 2026-02-05, showcasing a revenue of 0.00 against an estimate of 336.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.6 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ARWR's FY2026Q1 earnings announcement on 2026-02-05, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, ARWR's stock price tends to shift by an average of -1.24% in the 10 days leading up to earnings and +7.47% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate ARWR’s annual revenue to reach 245.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 6.2% and EPS estimates Revise Upward by 0.23% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ARWR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 6.2%, while EPS estimates moved Revise Upward by 0.23% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ARWR's stock price typically moves by -1.24% in the 10 days before its earnings and +7.47% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.00 and revenue of 245.00M.

The earnings call highlights strong financial performance, strategic partnerships, and promising product development, such as the plozasiran launch and multiple drug pipelines. Despite some uncertainties in clinical trial outcomes and regulatory claims, the overall sentiment remains positive due to solid financial health, strategic partnerships, and optimistic guidance. The market cap suggests a moderate reaction, likely resulting in a positive stock price movement of 2% to 8% over the next two weeks.